Clinical Trials Logo

Papulopustular Rosacea clinical trials

View clinical trials related to Papulopustular Rosacea.

Filter by:

NCT ID: NCT01025635 Completed - Clinical trials for Papulopustular Rosacea

Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Start date: December 2009
Phase: Phase 2
Study type: Interventional

This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.

NCT ID: NCT00855595 Completed - Clinical trials for Papulopustular Rosacea

Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea

Start date: February 2009
Phase: Phase 4
Study type: Interventional

Subjects with moderate papulopustular rosacea will be treated either with azelaic acid 15% gel topically plus an anti-inflammatory dose of doxycyline (40mg) daily or with metronidazole 1% gel topically once daily plus an anti-inflammatory dose of doxycycline (40mg) over at total of twelve weeks to determine the rapidity of improvement, and the length of time to reach 25%, 50% and 75% clearing compared to baseline.

NCT ID: NCT00617903 Completed - Clinical trials for Papulopustular Rosacea

Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.

NCT ID: NCT00417937 Completed - Clinical trials for Papulopustular Rosacea

A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily

Start date: January 2007
Phase: Phase 4
Study type: Interventional

To assess the efficacy and tolerability of azelaic acid 15% gel applied once daily versus twice daily in the treatment of patients with papulopustular rosacea.